KYTX – kyverna therapeutics, inc. (US:NASDAQ)

News

2 ‘Strong Buy' Biotech Stocks With 208% to 329% Upside Potential [Yahoo! Finance]
Kyverna Therapeutics (NASDAQ:KYTX) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
Kyverna Therapeutics (NASDAQ:KYTX) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.
Kyverna Therapeutics (NASDAQ:KYTX) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
Kyverna Therapeutics GAAP EPS of -$0.85 misses by $0.04 [Seeking Alpha]
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com